Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Gains from Investment Securities (2016 - 2025)

Seres Therapeutics' Gains from Investment Securities history spans 11 years, with the latest figure at $546805.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 93.01% year-over-year to $546805.0; the TTM value through Sep 2025 reached $546805.0, down 93.01%, while the annual FY2024 figure was $886123.0, 94.03% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was $546805.0 at Seres Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $7.8 million in Q3 2024 and bottomed at -$1.6 million in Q4 2023.
  • The 5-year median for Gains from Investment Securities is $546805.0 (2025), against an average of $1.1 million.
  • The largest annual shift saw Gains from Investment Securities crashed 149.67% in 2024 before it skyrocketed 574.49% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$112000.0 in 2021, then soared by 740.64% to $717514.0 in 2022, then tumbled by 316.58% to -$1.6 million in 2023, then soared by 118.85% to $293000.0 in 2024, then soared by 86.62% to $546805.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Gains from Investment Securities are $546805.0 (Q3 2025), $1.2 million (Q2 2025), and $293000.0 (Q4 2024).